Bioactivity | (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2]. | ||||||||||||
Invitro | The plasma concentrations of (R)-lansoprazole are remarkably higher in all three CYP2C19 genotype groups than those of the corresponding (S)-enantiomer. The AUC0-∞ Cmax and elimination half-life of (R)-lansoprazole are significantly greater and longer, respectively, than those of the (S)-enantiomer for all three genotype groups[3]. | ||||||||||||
Name | (R)-Lansoprazole | ||||||||||||
CAS | 138530-94-6 | ||||||||||||
Formula | C16H14F3N3O2S | ||||||||||||
Molar Mass | 369.36 | ||||||||||||
Appearance | Solid | ||||||||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
Storage |
|
||||||||||||
Reference | [1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [3]. M Miura, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8. |